PharmAsia Newsmaker Documents: Landmark Bayer IP Decision In India
This article was originally published in PharmAsia News
Executive Summary
In a new periodic feature, PharmAsia News highlights key regulatory and legal documents impacting biopharma and medical device companies doing business in Asia.
You may also be interested in...
Indian Court Nixes Bayer's Nexavar Patent Plea; Cipla Allowed To Market Generic Versions
MUMBAI - In a landmark decision that will further restrict multinational drug companies from introducing their internationally marketed brands in India, the Delhi High Court rejected German drug maker Bayer's plea to stop the Drug Controller General of India - the Indian drug regulator - from granting marketing approval to generic drug maker Cipla for kidney/liver cancer drug Nexavar (sorafenib)
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).